Annovis Bio reported a net loss of $41.9 million for the nine months ended September 30, 2026, compared to $19.0 million in the prior year, driven primarily by a significant increase in research and development expenses. The company's cash position decreased to $2.8 million from $19.5 million at the end of 2025, though it raised approximately $30.2 million through equity and warrant issuances during the period.
For the nine months ended September 30, 2026, FDCTech reported a significant revenue increase to $35.9 million compared to $17.3 million in the prior year, driven largely by its Brokerage (Trading) segment. Net income attributable to shareholders rose to $8.26 million, though the company experienced a net loss of $6.32 million in the third quarter of 2026 due to high costs of sales and operating expenses.
DSS, INC. reported a total revenue of $11.5 million for the nine months ended September 30, 2026, a decrease from $16.6 million in the prior year period. The company experienced a net loss of $16.3 million during this period, driven by higher operating costs and losses on investments, resulting in a total stockholders' equity of $4.3 million.
Microbot Medical Inc. reported a net loss of $15.14 million for the nine months ended September 30, 2026, compared to $9.68 million in the prior year, as the company began generating initial revenues of $418,000. Operating expenses increased significantly, particularly in sales and marketing, while cash and marketable securities decreased to approximately $61.8 million.
Peraso Inc. reported a significant decline in total net revenue to $0.3 million for the third quarter of 2026, down from $3.2 million in the prior year period, primarily due to lower product sales. The company's net loss widened to $2.7 million for the quarter, and cash reserves decreased to $0.6 million as of September 30, 2026, compared to $2.9 million at the end of 2025.
General Catalyst Global Resilience Merger Corp. is a blank check company that completed its IPO on May 1, 2026, raising $402.5 million. For the period from inception through September 30, 2026, the company reported net income of $5.17 million, primarily driven by $5.89 million in interest earned on cash held in the Trust Account, offset by $0.72 million in operating expenses.
Vuzix Corporation reported third quarter 2026 financial results, showing a 38% revenue decline to $0.7 million as the company transitions toward an OEM-focused business model. The company reported a net loss of $8.4 million ($0.10 per share) while highlighting progress in its defense business and the launch of its Causeway optical interconnect platform.
Term
Q3 2026
“During the third quarter, Vuzix continued to advance its transition towards a more OEM-focused business built around advanced waveguide technologies, optical engineering and its U.S.-based manufacturing capabilities.”
TRex Bio, Inc. is a clinical-stage biopharmaceutical company that has incurred substantial losses since inception and expects these losses to increase as it develops its autoimmune and inflammatory disease product candidates. As of November 5, 2026, the company had 28,788,654 shares of common stock outstanding and is classified as an emerging growth company.
CH4 Natural Solutions Corp reported a net loss of $4.15 million for the nine months ended September 30, 2026, primarily driven by $7.44 million in general and administrative expenses. The company completed its initial public offering in May 2026, resulting in $223.3 million held in a Trust Account and a significant shareholders' deficit of $14.4 million.
Aperture AC is a shell company that consummated its IPO on May 22, 2026, and has entered into a Business Combination Agreement with Atlantic HPC Group Inc. as of September 10, 2026. As of November 13, 2026, the company reported 10,961,000 Class A and 3,772,603 Class B Ordinary Shares outstanding.
Nuvve Holding Corp. reported third quarter 2026 revenue of $1.09 million, a 31.9% decrease year-over-year primarily due to lower customer sales orders and shipments. The company reported a cash operating loss of $4.3 million and highlighted the development of its Astrea AI-powered forecasting platform for utilities.
Term
Q3 2026
“As we look out to the next several quarters, we expect to see more developments on our European, Japan and New Mexico stationery battery pipeline projects. We also anticipate improvements in our cash burn resulting from the benefits of lower operating costs compared with last year. In parallel, we are bringing Astrea, our Artificial Intelligence ("AI") AI-powered forecasting and grid decision-support platform, to utilities and electric cooperatives, and we are preparing initial technical evaluations with prospective customers.”
Legato Merger Corp. IV reported net income of $4,202,267 for the fiscal year ended August 31, 2026, primarily driven by $4,897,509 in interest income from its trust account. As a blank check company, it has not yet generated operating revenue and is currently searching for a target business for its initial business combination.
Indaptus Therapeutics reported its Q3 2026 financial results, highlighting a cash and short-term investment position of approximately $30.6 million following a $24 million private placement. The company is shifting its strategic focus toward neurotechnology and neural-network-based devices for sleep-related conditions while significantly reducing R&D expenses by 82% year-over-year.
“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”
Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”
Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
IRulya Therapeutics (formerly Quince Therapeutics) reported Q3 2026 financial results and provided a corporate update following its recent rebranding and leadership appointments. The company ended the quarter with $105.2 million in cash, which is expected to fund operations through 2028, supporting Phase 2 clinical readouts for its lead candidate LAM-001 in pulmonary diseases.
Term
Q3 2026
“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases. By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions. With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
TPG Private Equity Opportunities, L.P. is an emerging growth company that invests primarily through the T-POP US Aggregator (CYM), L.P. As of November 10, 2026, the fund had approximately 62.3 million limited partnership units outstanding across seven different classes, including Class I and Class R-S as the largest components.
Evernorth Holdings Inc. reported its third-quarter 2026 financial results, highlighting continued growth in its pharmacy benefit management and specialty pharmacy segments. The filing indicates a focus on expanding specialty pharmacy capabilities and managing medical cost trends effectively while maintaining stable full-year guidance.
For the quarter ended September 30, 2026, eGain reported total revenue of $21.9 million, a decrease from $23.5 million in the prior year, primarily driven by lower SaaS and professional services revenue. Net income declined to $1.55 million ($0.06 per diluted share) compared to $2.82 million ($0.10 per diluted share) in the same period last year. The company continued its share repurchase program, spending $3.6 million to buy back 644,000 shares during the quarter.
NIQ Global Intelligence reported Q3 2026 financial results, achieving positive GAAP EPS for the first time since its IPO with net income of $35.8 million. The company exceeded guidance across all key metrics, raised its full-year 2026 outlook, and announced a new $150 million share repurchase authorization after reaching its net leverage target ahead of schedule.
“Q3 was a milestone quarter — we exceeded the top end of our guidance across all key metrics for the sixth consecutive quarter, delivered positive GAAP earnings per share for the first time since our IPO, and reached our net leverage milestone a quarter ahead of plan.”
Jim Peck, Executive Chairman and Chief Executive Officer
Core University Living Real Estate Income Trust commenced operations in July 2026, acquiring an initial portfolio of four student housing properties for approximately $300.5 million. For the period from formation through September 30, 2026, the company reported a net loss of $2.8 million on rental revenues of $6.3 million, primarily due to depreciation, interest expense, and general and administrative costs.
As of September 30, 2026, the Hashdex Nasdaq CME Crypto Index ETF reported net assets of $498.3 million, a significant increase from $121.3 million at the end of 2025. The Trust's portfolio is heavily weighted in Bitcoin (73.79%) and Ethereum (11.98%), and it recently transitioned its reference index to the Nasdaq CME Crypto Settlement Price Index in January 2026.
Vine Hill Capital Investment Corp. II reported net income of $4.97 million for the nine months ended September 30, 2026, primarily driven by $6.25 million in interest income from its Trust Account. As a shell company, it continues to seek an initial business combination while maintaining $236.5 million in Class A ordinary shares subject to possible redemption.
FiEE, Inc. reported a significant turnaround for the nine months ended September 30, 2026, achieving net income of $3.58 million compared to a net loss of $1.27 million in the prior year period. This growth was driven by a substantial increase in revenues to $9.57 million, up from $1.98 million, alongside the acquisition of new subsidiaries.
Suncrete, Inc. filed an amendment to its Q3 2026 earnings report to correct errors in its full-year 2026 outlook caused by a technical disruption. The company updated its projected net loss to a range of $43.7M to $39.7M and its adjusted net loss to $16.8M to $12.8M, while maintaining its previously issued revenue and Adjusted EBITDA guidance.
Next Bridge Hydrocarbons, Inc. reported 288,458,813 shares of common stock outstanding as of November 13, 2026. The filing indicates the company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, with financial statements covering the quarter ended September 30, 2026.
Annovis Bio reported third quarter 2026 financial results and provided a clinical update on its Phase 3 DUET-AD study for Alzheimer's disease, with a data readout expected in March 2027. The company also highlighted a $21.0 million capital raise from an underwritten public offering intended to fund operations through the upcoming clinical milestones.
Term
Q3 2026
“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA). We now have dates set for last patient, last visit of the 6-month treatment period and for database lock, as well as financing in place to carry us through topline results in March 2027. The team is working very hard to deliver clean data and an on-time readout.”
Maria Maccecchini, PhD, President and CEO of Annovis
For the nine months ended September 30, 2026, Versus Systems reported total revenues of $1.51 million, primarily driven by related party transactions, and a net loss of $0.89 million. The company strengthened its balance sheet through the issuance of common stock, raising $1.7 million in financing during the period.
For the nine months ended September 30, 2026, Fidelity Private Credit Co LLC reported total investment income of $124.4 million and net expenses of $57.0 million. The company completed a merger on July 31, 2026, with Fidelity Private Credit Company II LLC, resulting in a net asset value per unit of $10.25 as of the end of the period.
For the three months ended September 30, 2026, Paramount Gold Nevada Corp. reported a net loss of $4.56 million, compared to a $4.32 million loss in the prior year period. The loss was primarily driven by non-cash items, including a $2.09 million loss from the change in fair value of derivative liabilities and a $346,706 loss from the change in fair value of warrant liabilities.
Koil Energy Solutions reported a significant revenue increase to $10.3 million for the quarter ended September 30, 2026, compared to $6.4 million in the prior year. The company achieved a net income of $0.2 million for the quarter, a turnaround from a net loss of $0.4 million in the same period of 2025.
Stonepeak-Plus Infrastructure Fund LP is an emerging growth company that conducts its investment activities primarily through the Master Aggregator. As of October 16, 2026, the registrant reported a complex capital structure with over 34 million units outstanding across various classes, including Class Z and Class X units.